Open AccessFocus on Silodosin: Pros and Cons of Uroselectivity
Author(s) -
Gianluigi Califano,
Claudia Collà Ruvolo,
Massimiliano Creta,
Marco Capece,
Roberto La Rocca,
Giuseppe Celentano,
Luigi Napolitano,
Francesco Paolo Calace,
Gianluca Spena,
Francesco Trama,
Felice Crocetto,
Francesco Mangiapia,
Nicola Longo,
Ferdinando Fusco
Publication year - 2020
Publication title -
research and reports in urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.506
H-Index - 20
ISSN - 2253-2447
DOI - 10.2147/rru.s287129
Subject(s) - silodosin , medicine , tolerability , lower urinary tract symptoms , bladder outlet obstruction , urology , overactive bladder , hyperplasia , prostate , adverse effect , alternative medicine , pathology , cancer
Medical management of lower urinary tract symptoms related to benign prostatic obstruction engages healthcare professionals worldwide. Currently, alpha-1 adrenergic antagonists are strongly recommended as first-line therapy for patients with moderate to severe symptoms because of their safety, efficacy and good tolerability. These agents are highly heterogeneous in terms of pharmacological selectivity for the adrenergic receptor subtypes with silodosin being the agent characterized by the highest α 1A /α 1B affinity ratio. This property has been proposed to confer to silodosin advantages in terms of bladder outlet obstruction improvement and lower incidence of cardiovascular side effects at the cost of a higher incidence of ejaculatory dysfunction. These aspects should be carefully taken in consideration when personalizing medical therapy for lower urinary tract symptoms related to benign prostatic obstruction.